Critical Insights From Geron Analyst Ratings: What You Need To Know


Analysts' ratings for Geron GERN over the last quarter vary from bullish to bearish, as provided by 12 analysts.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 8 3 1 0 0
Last 30D 1 0 0 0 0
1M Ago 1 1 0 0 0
2M Ago 3 0 1 0 0
3M Ago 3 2 0 0 0

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $5.88, a high estimate of $10.00, and a low estimate of $4.00. This current average reflects an increase of 13.08% from the previous average price target of $5.20.

Interpreting Analyst Ratings: A Closer Look

The standing of Geron among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Stephen Willey Stifel Raises Buy $7.00 $6.00
Gil Blum Needham Raises Buy $6.00 $5.00
Robert Driscoll Wedbush Maintains Outperform $7.00 $7.00
Gil Blum Needham Maintains Buy $5.00 -
Joel Beatty Baird Maintains Neutral $4.50 -
Tara Bancroft TD Cowen Announces Buy $10.00 -
Gil Blum Needham Maintains Buy $5.00 -
Robert Driscoll Wedbush Maintains Outperform $6.00 -
Gil Blum Needham Raises Buy $5.00 $4.00
Corinne Jenkins Goldman Sachs Raises Buy $5.00 $4.00
Robert Driscoll Wedbush Maintains Outperform $6.00 -
Gil Blum Needham Maintains Buy $4.00 -

Key Insights:

  • Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Geron. This offers insight into analysts' perspectives on the current state of the company.
  • Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Geron compared to the broader market.
  • Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Geron's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Geron's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on Geron analyst ratings.

Unveiling the Story Behind Geron

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Unraveling the Financial Story of Geron

Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.

Revenue Growth: Geron displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 1347.62%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Geron's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -18220.39%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Geron's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -18.69%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Geron's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -12.64%, the company may face hurdles in achieving optimal financial performance.

Debt Management: Geron's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.25.

Analyst Ratings: What Are They?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!